Developing high‑potency softgels requires precise containment, disciplined process control, and documentation that meets the expectations of regulated markets. Douglas CDMO provides FDA‑aligned HPAPI softgel development, supported by validated cleaning strategies, proven scale‑up methodologies, and the quality maturity expected for U.S./EU submissions.
Why choose Douglas CDMO for HPAPI softgels
High‑potency softgels introduce challenges that standard oral‑dose manufacturers are not structured to handle, including dust risk, analytical sensitivity, cleaning difficulty, and tight containment requirements.
Douglas CDMO brings more than 30 years of high‑potency experience and deep softgel expertise, supported by systems and practices designed to manage the risks of lipid‑based HPAPI development.
Inspection‑ready HPAPI and softgel systems
Douglas CDMO maintains HPAPI‑capable softgel suites designed for reliable performance through development, scale‑up, and commercial readiness.
We operate with:
- Validated containment approaches for potent and light‑sensitive APIs
- Specialised cleaning validation supporting lipid‑based and HPAPI matrices
- Data‑integrity discipline embedded across development and manufacturing
- Batch documentation aligned with FDA/EMA expectations
- Inspection‑ready systems supporting global submissions
Reliable HPAPI tech transfer and scale‑up
Our HPAPI softgel transfer process is structured to reduce risk and maintain momentum. Clear frameworks, tightly defined responsibilities, and rapid access to specialists help ensure a smooth transition into manufacturing.
We provide:
- HPAPI method transfer and verification
- Process controls with proven acceptable ranges
- Transparent timelines and consistent communication
- Scale‑up pathways aligned with FDA/EMA expectations
- HPAPI softgel PPQ you can trust, underpinned by reproducible process behaviour
This gives clients confidence that their high‑potency softgel can move efficiently from development into PPQ and commercial supply.
Regulatory‑grade documentation for U.S./EU markets
Douglas CDMO prepares CMC and PPQ packages that clearly communicate the rationale, control strategy, analytical validation, and cleaning approaches required for high‑potency softgels
Our documentation is designed to:
- Support U.S. IND/NDA and EU submission pathways
- Demonstrate control over potency‑related risks
- Provide clarity around design space and process parameters
- Reduce regulatory questions and late‑stage rework
Your program progresses with documentation built for scrutiny.
High‑quality HPAPI softgels for regulated markets
Douglas has extensive experience developing high‑potency softgels for oncology, immunology, dermatology, and specialised therapeutics. Our teams are trained in potent‑compound handling, and our systems are engineered to manage the complexity of lipid‑based HPAPI products at every stage.
This includes:
- Exposure‑controlled material handling
- Validated cleaning limits for potent lipid residues
- Sensitive analytical methods suitable for low‑dose APIs
- Robust in‑process checks supporting dose uniformity and safety
A CDMO partner for complex, high‑potency programs
Douglas CDMO is ideal for teams needing:
- An agile, responsive partner for HPAPI softgel development
- FDA‑aligned processes and inspection‑ready facilities
- Predictable scale‑up without big‑CDMO delays
- High‑potency controls integrated into every stage
- A pathway from development → PPQ → commercial supply
Recognition and awards
The FDA’s Quality Management Maturity Pilot Study
In 2024, Douglas was one of only nine companies selected globally to participate in this ongoing, in-depth review of our processes that contribute to our ability to deliver the right quality products on time.